Sign In
Buy CBAY
$32.48
+0 (+0%)
At Close: Apr 11, 2024
CymaBay Therapeutics (NASDAQ:CBAY) Stock Price Down 7.1%
07:26am, Friday, 06'th Mar 2020
CymaBay Therapeutics Inc (NASDAQ:CBAY)’s stock price was down 7.1% during mid-day trading on Thursday . The stock traded as low as $1.71 and last traded at $1.71, approximately 779,984 shares change
SAN FRANCISCO, CA / ACCESSWIRE / March 5, 2020 / Hagens Berman urges investors in CymaBay Therapeutics, Inc. (NASDAQ:CBAY) who have suffered significant losses to submit their losses now . The firm is
CymaBay Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, March 12
09:01pm, Thursday, 05'th Mar 2020
NEWARK, Calif., March 05, 2020 -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other.
LOS ANGELES, CA / ACCESSWIRE / March 5, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CymaBay Therapeut
California Public Employees Retirement System Has $189,000 Stock Holdings in CymaBay Therapeutics Inc (NASDAQ:CBAY)
03:22pm, Thursday, 05'th Mar 2020
California Public Employees Retirement System increased its position in CymaBay Therapeutics Inc (NASDAQ:CBAY) by 368.0% in the 4th quarter, according to the company in its most recent 13F filing with
CymaBay Therapeutics to Report Fourth Quarter and Full Year —…–9 Financial Results on ...
12:00am, Thursday, 05'th Mar 2020
NEW YORK--(BUSINESS WIRE)-- #CBAY--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against CymaBay Therapeutics, Inc.
